In a nutshell
This study looked at the effect of canagliflozin (Invokana) on hospitalization occurrence in patients with type 2 diabetes (T2D). It found that patients treated with canagliflozin were less likely to be admitted to the hospital than patients treated with placebo.
Some background
Canagliflozin is a medication used to treat T2D. It works by increasing the amount of glucose (sugar) removed by the kidneys. Patients with T2D can develop a number of health-related problems. They are frequently admitted to the hospital. It is not clear whether treatment with canagliflozin affects the rate of hospitalization in patients with T2D.
Methods & findings
10,142 patients with T2D were involved in this study. Patients were divided into 2 groups. One group was treated with cangliflozin, the other group was treated with a placebo. Patients were followed up for an average of 2.4 years.
There were 7,115 episodes of hospitalization throughout the study. The most common reasons for hospitalization were heart disease (23.7%) and infections (15%). Patients in the canagliflozin group were 8% less likely to be hospitalized than patients in the placebo group, overall. Patients in the canagliflozin group were 19% less likely to be hospitalized due to heart disease than the placebo group.
The bottom line
This study showed that patients treated with canagliflozin were less likely to be hospitalized with heart disease than patients treated with a placebo.
The fine print
This study was funded by Janssen, the manufacturer of canagliflozin.
Published By :
Diabetes, Obesity and Metabolism
Date :
Aug 17, 2021
